프로티나 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 안정현, was filed 30 Apr 2026.
프로티나: what insiders have been doing
Every trade that managers of 프로티나 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 2 November 2026, 20 filings were filed, from 11 insiders.
Both sides are active: 17 purchases worth €619k and 1 sale, from 10 insiders and 1 insider respectively. No amount is published for 9 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €391k from 윤태영, disclosed on 30 April 2026, or 0.17% of market capitalisation. Among those who bought: 7 board members and 2 senior executives.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 20 filings here. Looking back to 2025, when coverage begins, insiders filed 27 purchases and 4 sales.
Within a 30-day window, 9 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 30 April 2026, 193 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 3 days. That lag is the time during which only the insider knows about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySale+8 other insiders
Since the insiders bought
- -1.6%Entry ₩55,200 · Close 30 Oct 2026 ₩54,300
- -1.6%Entry ₩55,200 · Close 30 Oct 2026 ₩54,300
- -1.6%Entry ₩55,200 · Close 30 Oct 2026 ₩54,300
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 3,400 shares@ ₩8,477.000.0072% mcap100.0% of flowShareKRXDART:20260430001836Canonical exit: 26 Jul 2026 (T+90)
- 719 shares@ ₩7,280.000.0013% mcap100.0% of flowShareKRXDART:20260430001847Canonical exit: 26 Jul 2026 (T+90)
- 3,518 shares@ ₩8,357.91250.0074% mcap100.0% of flowShareKRXDART:20260430001865Canonical exit: 26 Jul 2026 (T+90)
- 12,000 shares0.17% mcap100.0% of flowKRXDART:20260430001810Canonical exit: 26 Jul 2026 (T+90)
- 3,000 shares@ ₩8,477.000.0064% mcap100.0% of flowShareKRXDART:20260430001878Canonical exit: 26 Jul 2026 (T+90)
- 1,800 shares@ ₩4,158.000.0019% mcap100.0% of flowShareKRXDART:20260430001841Canonical exit: 26 Jul 2026 (T+90)
- 3,343 shares@ ₩3,780.000.0032% mcap100.0% of flowShareKRXDART:20260430001829Canonical exit: 26 Jul 2026 (T+90)
- 68,000 shares@ ₩3,780.000.065% mcap100.0% of flowShareKRXDART:20260430001824Canonical exit: 26 Jul 2026 (T+90)
- 3,368 shares@ ₩8,220.52730.0069% mcap100.0% of flowShareKRXDART:20260430001816Canonical exit: 26 Jul 2026 (T+90)
- ●Executives0DART
- 3,000 sharesShareKRXDART:20251230000619
- 2,000 sharesShareKRXDART:20251127001285Canonical exit: 25 Feb 2026 (T+90)
- ●Executives0DART
- 3,133 sharesShareKRXDART:20251127001241Canonical exit: 25 Feb 2026 (T+90)
- 3,315 sharesShareKRXDART:20251127001253Canonical exit: 25 Feb 2026 (T+90)
- 3,315 sharesShareKRXDART:20251127001299Canonical exit: 25 Feb 2026 (T+90)
- 3,133 sharesShareKRXDART:20251127001233Canonical exit: 25 Feb 2026 (T+90)
- 3,382 sharesShareKRXDART:20251127001260Canonical exit: 25 Feb 2026 (T+90)
25 of 40 declarations
About 프로티나
Protinah is a company operating in the health and pharmaceutical sector, listed on the XKRX. It specializes in the development of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations